GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Perspective Therapeutics Inc (AMEX:CATX) » Definitions » ROA %

CATX (Perspective Therapeutics) ROA % : -15.57% (As of Sep. 2024)


View and export this data going back to 2005. Start your Free Trial

What is Perspective Therapeutics ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Perspective Therapeutics's annualized Net Income for the quarter that ended in Sep. 2024 was $-60.49 Mil. Perspective Therapeutics's average Total Assets over the quarter that ended in Sep. 2024 was $388.54 Mil. Therefore, Perspective Therapeutics's annualized ROA % for the quarter that ended in Sep. 2024 was -15.57%.

The historical rank and industry rank for Perspective Therapeutics's ROA % or its related term are showing as below:

CATX' s ROA % Range Over the Past 10 Years
Min: -67.94   Med: -36.75   Max: -8.56
Current: -25.24

During the past 13 years, Perspective Therapeutics's highest ROA % was -8.56%. The lowest was -67.94%. And the median was -36.75%.

CATX's ROA % is ranked worse than
70.62% of 868 companies
in the Medical Devices & Instruments industry
Industry Median: -2.04 vs CATX: -25.24

Perspective Therapeutics ROA % Historical Data

The historical data trend for Perspective Therapeutics's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Perspective Therapeutics ROA % Chart

Perspective Therapeutics Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Dec23
ROA %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -60.96 -38.03 -8.56 -10.78 -57.30

Perspective Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -35.92 -94.72 -26.12 -14.10 -15.57

Competitive Comparison of Perspective Therapeutics's ROA %

For the Medical Devices subindustry, Perspective Therapeutics's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Perspective Therapeutics's ROA % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Perspective Therapeutics's ROA % distribution charts can be found below:

* The bar in red indicates where Perspective Therapeutics's ROA % falls into.



Perspective Therapeutics ROA % Calculation

Perspective Therapeutics's annualized ROA % for the fiscal year that ended in Dec. 2023 is calculated as:

ROA %=Net Income (A: Dec. 2023 )/( (Total Assets (A: Jun. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=-46.508/( (64.439+97.891)/ 2 )
=-46.508/81.165
=-57.30 %

Perspective Therapeutics's annualized ROA % for the quarter that ended in Sep. 2024 is calculated as:

ROA %=Net Income (Q: Sep. 2024 )/( (Total Assets (Q: Jun. 2024 )+Total Assets (Q: Sep. 2024 ))/ count )
=-60.488/( (385.919+391.153)/ 2 )
=-60.488/388.536
=-15.57 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Sep. 2024) net income data. ROA % is displayed in the 30-year financial page.


Perspective Therapeutics  (AMEX:CATX) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Sep. 2024 )
=Net Income/Total Assets
=-60.488/388.536
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-60.488 / 0)*(0 / 388.536)
=Net Margin %*Asset Turnover
=N/A %*0
=-15.57 %

Note: The Net Income data used here is four times the quarterly (Sep. 2024) net income data. The Revenue data used here is four times the quarterly (Sep. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Perspective Therapeutics ROA % Related Terms

Thank you for viewing the detailed overview of Perspective Therapeutics's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


Perspective Therapeutics Business Description

Traded in Other Exchanges
Address
2401 Elliott Avenue, Suite 320, Seattle, WA, USA, 98121
Perspective Therapeutics Inc is a medical technology and radiopharmaceutical company that is pioneering various treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides.
Executives
Johan M. Spoor director, officer: CEO 500 BOYLSTON STREET, SUITE 1600, BOSTON MA 02116
Jonathan Robert Hunt officer: Chief Financial Officer 350 HILLS STREET, SUITE 106, RICHLAND WA 99354
Williamson Robert F Iii director 140 LASALLE AVENUE, PIEDMONT CA 94610
Lori A Woods officer: Vice President 350 HILLS STREET, SUITE 106, RICHLAND WA 99354
Markus Puhlmann officer: Chief Medical Officer 350 HILLS STREET, SUITE 106, RICHLAND WA 99354
Heidi Henson director 2173 SALK AVENUE, SUITE 250, PMB#052, CARLSBAD CA 92008
Frank Morich director 40 GUEST STREET, BOSTON MA 02135
Mark John Austin officer: Controller/Prin Fin&Acct Offic 350 HILLS ST, STE 106, RICHLAND WA 99354
Philip J Vitale director 8849 E. CALLE DE LAS BRISAS, SCOTTSDALE AZ 85255
Michael W Mccormick director 9923 EAST BELL ROAD, STE 130, SCOTTSDALE AZ 85260
William Cavanagh officer: Vice President 350 HILLS STREET, SUITE 106, RICHLAND WA 99354
Alan Hoffmann director 3030 EAST CACTUS ROAD, SUITE 101, PHOENIX AZ 85032
Michael Krachon officer: VP of Sales & Marketing 350 HILLS STREET, SUITE 106, RICHLAND WA 99354
Krista Cline officer: Dir. of Operations, Secretary 350 HILLS STREET, STE 106, RICHLAND WA 99354
Jennifer Streeter officer: VP of Human Resources 350 HILLS STREET SUITE 106, RICHLAND WA 99354